Evonik meets 2025 guidance, confirms 2026 earnings outlook
Evonik has met its profit guidance for 2025 and reaffirmed its outlook for 2026. Outlook 2026 for adjusted EBITDA between €1.7 and €2.0 billion affirmed ... MORE
Evonik has met its profit guidance for 2025 and reaffirmed its outlook for 2026. Outlook 2026 for adjusted EBITDA between €1.7 and €2.0 billion affirmed ... MORE
Evonik is reinforcing its growth strategy by further strengthening its global production infrastructure for hydroxyl-terminated polybutadienes (HTPB). ... MORE
The Executive Board discussed Evonik's dividend policy based on the preliminary results for 2025 and the outlook for 2026. As reported in an ad hoc announcement earlier today, Evonik targets an annual shareholder distribution of between 40 and 60 percent of adjusted net income starting with the 2026 financial year. ... MORE
Evonik Coating Additives introduces TEGO® Dispers 695, a novel hyperdispersant for radiation-curing inks and solventborne polyurethane inks. ... MORE
Evonik has entered a strategic partnership with InVitria, a leading developer of recombinant proteins and supplements, to supply animal component-free (ACF) recombinant human serum albumin to the global biopharmaceutical industry. ... MORE
Evonik and HosenCare officially announced the launch of a new China-focused innovation fund—Jinjiang Houxin—during the 8th China International Import Expo. The fund is jointly initiated with multiple partners to deepen local innovation collaboration and accelerate the commercialization of high-quality, sustainable technologies in China. ... MORE